医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
4期
31-32
,共2页
张延霞%金正贤(通讯作者)%王利群%苏玉文
張延霞%金正賢(通訊作者)%王利群%囌玉文
장연하%금정현(통신작자)%왕리군%소옥문
多奈哌齐%尼莫地平%血管性痴呆%临床观察
多奈哌齊%尼莫地平%血管性癡呆%臨床觀察
다내고제%니막지평%혈관성치태%림상관찰
Donepezil%nimodipine%vascular dementia%clinical observation
目的:通过观察多奈哌齐联合尼莫地平片治疗VD的疗效和治疗前后MMSE、ADL评分的变化,了解其临床应用的可行性。方法选择2010.6~2013.11我科收治的脑梗死患者96例,对患者进行 MMSE量表测评,依据得分情况分为对照组(C 组)与血管性痴呆组(VD 组),其中VD组再分为多奈哌齐联合尼莫地平治疗组(即联合治疗组)和单纯加服尼莫地平治疗组(尼莫地平组),其中联合治疗组男24例,女8例,平均78.8岁;尼莫地平组男23例,女9例,平均77.5岁;对照组男21例,女11例,平均77.3岁,三组均给予相同的活血化瘀药物等常规治疗及对症处理,联合治疗组在此基础上给予口服多奈哌齐及尼莫地平,尼莫地平组在此基础上给予口服尼莫地平,8W、12W后行MMSE 、ADL评分及计算有效率。结果8W、12W后,三组患者的MMSE 评分、ADL 评分均升高,其中,联合治疗组8W、12W后评分均高于对照组和尼莫地平组(P<0.01),尼莫地平组12W后评分高于对照组(P<0.05)。临床疗效比较,联合治疗组8W、12W后总有效率明显高于对照组与尼莫地平组(P<0.01);尼莫地平组12W后总有效率明显高于对照组(P<0.05)。结论多奈哌齐联合尼莫地平治疗血管性痴呆疗效显著,无明显不良反应,临床中值得推广。
目的:通過觀察多奈哌齊聯閤尼莫地平片治療VD的療效和治療前後MMSE、ADL評分的變化,瞭解其臨床應用的可行性。方法選擇2010.6~2013.11我科收治的腦梗死患者96例,對患者進行 MMSE量錶測評,依據得分情況分為對照組(C 組)與血管性癡呆組(VD 組),其中VD組再分為多奈哌齊聯閤尼莫地平治療組(即聯閤治療組)和單純加服尼莫地平治療組(尼莫地平組),其中聯閤治療組男24例,女8例,平均78.8歲;尼莫地平組男23例,女9例,平均77.5歲;對照組男21例,女11例,平均77.3歲,三組均給予相同的活血化瘀藥物等常規治療及對癥處理,聯閤治療組在此基礎上給予口服多奈哌齊及尼莫地平,尼莫地平組在此基礎上給予口服尼莫地平,8W、12W後行MMSE 、ADL評分及計算有效率。結果8W、12W後,三組患者的MMSE 評分、ADL 評分均升高,其中,聯閤治療組8W、12W後評分均高于對照組和尼莫地平組(P<0.01),尼莫地平組12W後評分高于對照組(P<0.05)。臨床療效比較,聯閤治療組8W、12W後總有效率明顯高于對照組與尼莫地平組(P<0.01);尼莫地平組12W後總有效率明顯高于對照組(P<0.05)。結論多奈哌齊聯閤尼莫地平治療血管性癡呆療效顯著,無明顯不良反應,臨床中值得推廣。
목적:통과관찰다내고제연합니막지평편치료VD적료효화치료전후MMSE、ADL평분적변화,료해기림상응용적가행성。방법선택2010.6~2013.11아과수치적뇌경사환자96례,대환자진행 MMSE량표측평,의거득분정황분위대조조(C 조)여혈관성치태조(VD 조),기중VD조재분위다내고제연합니막지평치료조(즉연합치료조)화단순가복니막지평치료조(니막지평조),기중연합치료조남24례,녀8례,평균78.8세;니막지평조남23례,녀9례,평균77.5세;대조조남21례,녀11례,평균77.3세,삼조균급여상동적활혈화어약물등상규치료급대증처리,연합치료조재차기출상급여구복다내고제급니막지평,니막지평조재차기출상급여구복니막지평,8W、12W후행MMSE 、ADL평분급계산유효솔。결과8W、12W후,삼조환자적MMSE 평분、ADL 평분균승고,기중,연합치료조8W、12W후평분균고우대조조화니막지평조(P<0.01),니막지평조12W후평분고우대조조(P<0.05)。림상료효비교,연합치료조8W、12W후총유효솔명현고우대조조여니막지평조(P<0.01);니막지평조12W후총유효솔명현고우대조조(P<0.05)。결론다내고제연합니막지평치료혈관성치태료효현저,무명현불량반응,림상중치득추엄。
Objective The clinical curative effect observation and treatment of donepezil and nimodipine in the treatment of vascular dementia and changes of MMSE, ADL scale, to understand the feasibility of clinical application. Methods Choose 2010.6 to 2013.11 in our hospital from 62 cases of cerebral infarction patients, patients with the MMSE scale, based on scores were divided into control group (group C) and vascular dementia group (VD group), VD group was further divided into donepezil and nimodipine treatment group (i.e. combined treatment group) and simple oral nimodipine in treatment group (nimodipine group), the combined treatment group male 24 cases, female 8 cases, average 78.8 years old; nimodipine group male 23 cases, female 9 cases, average 77.5 years old; the control group male 21 cases, female 11 cases, average 74.3 years old, The three groups were given intravenous drip of Huoxue Huayu drugs and other conventional treatment and symptomatic treatment, the treatment group based on the given oral donepezil and nimodipine, nimodipine group were given oral nimodipine, 8W, 12W MMSE, ADL score for evaluation of curative effect. Results 8W, 12W, three groups of patients with MMSE score, ADL score increased, which, combined treatment group 8W, 12W scores were higher than that of control group and nimodipine group (P<0.01), nimodipine group 12W was higher than that of the control group (P<0.05). Comparison of the clinical efficacy of combined therapy group, 8W, 12W after the total efficiency was significantly higher than that in control group and nimodipine group (P<0.01);nimodipine group 12W was better than that in control group (P<0.05).Conclusion Effect of donepezil and nimodipine in the treatment of vascular dementia significantly, no significant adverse reactions, worthy of promotion in clinical therapy.